Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb) in Patients With Metastatic or Recurrent Endometrial Cancer
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2019
Price : $35 *
At a glance
- Drugs VSV-IFNbeta-NIS (Primary) ; Technetium-99m
- Indications Adenocarcinoma; Endometrial cancer
- Focus Adverse reactions
- 02 Aug 2019 Planned End Date changed from 1 Jun 2020 to 30 Jun 2020.
- 24 Jun 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 24 Jun 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.